{"entity":{"id":"nct04176848","kind":"trial","name":"CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of CFI-400945 run by Canadian Cancer Trials Group, active and no longer recruiting.","summary":"CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer is a phase 2 interventional study registered as NCT04176848 by Canadian Cancer Trials Group, with 15 participants planned, started 2020-08-10. Conditions recorded: Breast Cancer. Interventions recorded: CFI-400945 and Durvalumab.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04176848","url":"https://clinicaltrials.gov/study/NCT04176848"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cfi-400945"],"companies":["treadwell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04176848","phase":"2","setting":"A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC)","sponsor":"Canadian Cancer Trials Group","enrolled":15,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04176848/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"cfi-400945","kind":"drug","name":"CFI-400945","route":"/drugs/cfi-400945/"}],"company":[{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/"}]}}